- Home
- XTNT vs EQ Comparison
XTNT vs EQ Comparison
Compare XTNT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- EQ
- Stock Information
- Founded
- XTNT N/A
- EQ 2017
- Country
- XTNT United States
- EQ United States
- Employees
- XTNT N/A
- EQ N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- EQ Health Care
- Exchange
- XTNT Nasdaq
- EQ Nasdaq
- Market Cap
- XTNT 89.8M
- EQ 85.1M
- IPO Year
- XTNT N/A
- EQ 2018
- Fundamental
- Price
- XTNT $0.73
- EQ $1.46
- Analyst Decision
- XTNT
- EQ Hold
- Analyst Count
- XTNT 0
- EQ 2
- Target Price
- XTNT N/A
- EQ $1.00
- AVG Volume (30 Days)
- XTNT 223.7K
- EQ 768.5K
- Earning Date
- XTNT 11-11-2025
- EQ 11-12-2025
- Dividend Yield
- XTNT N/A
- EQ N/A
- EPS Growth
- XTNT N/A
- EQ N/A
- EPS
- XTNT N/A
- EQ N/A
- Revenue
- XTNT $127,766,000.00
- EQ $16,553,000.00
- Revenue This Year
- XTNT $13.03
- EQ N/A
- Revenue Next Year
- XTNT N/A
- EQ N/A
- P/E Ratio
- XTNT N/A
- EQ N/A
- Revenue Growth
- XTNT 15.16
- EQ N/A
- 52 Week Low
- XTNT $0.33
- EQ $0.27
- 52 Week High
- XTNT $0.84
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- XTNT 57.33
- EQ 53.00
- Support Level
- XTNT $0.68
- EQ $1.17
- Resistance Level
- XTNT $0.84
- EQ $1.29
- Average True Range (ATR)
- XTNT 0.06
- EQ 0.12
- MACD
- XTNT 0.01
- EQ -0.01
- Stochastic Oscillator
- XTNT 49.45
- EQ 66.18
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.